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Abstract  26 
HIV-1 infection is characterised by the rapid generation of genetic diversity that facilitates viral 27 
escape from immune selection and antiretroviral therapy. Despite recombination’s crucial role in 28 
viral diversity and evolution, little is known about the genomic factors that influence recombination 29 
between highly similar genomes. In this study, we use a minimally modified full length HIV-1 genome 30 
and high throughput sequence analysis to study recombination in gag and pol in T cells. We find that 31 
recombination is favoured at a number of recombination hotspots, where recombination occurs six 32 
times more frequently than at corresponding coldspots. Interestingly, these hotspots occur near 33 
important features of the HIV-1 genome, but do not occur at sites immediately around protease 34 
inhibitor or reverse transcriptase inhibitor drug resistance mutations. We show that the 35 
recombination hot and cold spots are consistent across five blood donors and are independent of 36 
co-receptor mediated entry. Finally, we check common experimental confounders and find that 37 
these are not driving the location of recombination hotspots. This is the first study to identify the 38 
location of recombination hotspots, between two similar viral genomes with great statistical power 39 
and under conditions that closely reflect natural recombination events amongst HIV-1 quasispecies. 40 
Statement of importance 41 
The ability of HIV-1 to evade the immune system and antiretroviral therapy depends on genetic 42 
diversity within the viral quasispecies. Retroviral recombination is an important mechanism that 43 
helps to generate and maintain this genetic diversity, but little is known about how recombination 44 
rates vary within the HIV-1 genome. We measured recombination rates in gag and pol and identify 45 
recombination hot and cold spots demonstrating that recombination is not random, but depends on 46 
the underlying gene sequence. The strength and location of these recombination hot and cold spots 47 
can be used to improve models of viral dynamics and evolution, which will be useful for the design of 48 
robust antiretroviral therapies. 49 
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Introduction 50 
The high level of genetic diversity is one of the main contributors to immune system and drug 51 
treatment failure during human immunodeficiency virus type 1 (HIV-1) infection. This diversity is 52 
primarily generated by the error prone reverse transcriptase during DNA synthesis, a process that 53 
results in approximately one mutation every three-replication cycles (1-4). Moreover, each HIV-1 54 
virion contains two copies of the RNA genome, allowing the reverse transcriptase to switch between 55 
the two co-packaged RNA genomes. This process of recombination also influences HIV-1’s sequence 56 
diversity by generating a progeny that is a genetic mix of the two parental strains (5). Recombination 57 
occurs much more frequently than mutation and is a powerful force that influences the evolution of 58 
the HIV-1 genome (for review see reference (4)). Investigations into locations of inter/intra subtype 59 
recombination indicate that sequence identity is sufficient to explain most breakpoint locations (6-60 
9). This is unsurprising as sequence similarity between genomic partners is a strict requirement for 61 
efficient recombination (7, 10-12). Given that the vast majority of HIV-1 infections are not the result 62 
of co-infections with multiple divergent viral strains, but are initiated from a single virion, a model 63 
system that measures recombination between genetically similar genomes rather than inter/intra 64 
subtypes will better approximate the quasispecies in vivo (13-15). However, little is known about 65 
recombination likely to be found within the viral quasispecies of an infected individual because it is 66 
difficult to detect recombination between genetically similar genomes. Understanding 67 
recombination is a critical piece in the puzzle of HIV-1’s evolutionary history and may help with the 68 
development of future treatments or with vaccine design. 69 
Measuring recombination involves analysing the progeny of heterozygous virions (virions containing 70 
two genetically different genomes) to determine where recombination breakpoints exist, and at 71 
what frequency they are generated. Studies to date have measured recombination rates in a 72 
number of elegant ways. The use of retroviral reporter systems, where correctly positioned 73 
recombination will recreate a functional ‘foreign’ gene insert conferring antibiotic resistance or 74 
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fluorescence (16-18) allows for the rapid screening of recombinants, but does not allow the 75 
measurement of recombination on the natural HIV-1 sequence. A more direct method of detecting 76 
recombination is through the sequencing of reverse transcription products derived from an 77 
authentic HIV-1 replication cycle. Importantly, recombination can only be observed when it leads to 78 
the generation of chimeric molecules. That is, template switching between identical genomes, or an 79 
even number of template switches between two genetic loci will lead to no genetic changes and will 80 
go unobserved. Thus to detect recombination on the native HIV-1 genome, genetically different 81 
strains must be utilized. Previous studies have leveraged sequence differences between highly 82 
divergent but naturally occurring subtypes to measure intra or inter-subtype recombination (19-22). 83 
However, as the overall sequence similarity between RNA templates is a major driving force 84 
governing recombination (6, 7, 10, 12), and the majority of infected individuals harbour viral 85 
populations that are known to be genetically similar (14, 23), measurements of recombination 86 
between genetically divergent strains will only reflect the special case of inter/intra subtype 87 
recombination but will not reflect recombination amongst the genetically similar HIV-1 genomes 88 
found in most viral quasispecies. 89 
To address these issues, we developed a minimally codon modified HIV-1 genome and showed that 90 
this could be used to directly measure recombination under conditions where sequence similarity 91 
between RNA templates remains high (24). Using Sanger sequencing of single round reverse 92 
transcription products in the absence of selection, we showed that recombination does not occur 93 
randomly. This is in agreement with studies showing recombination rates depend on a complex set 94 
of factors, such as the availability of nucleotide substrates (25-27), the RNA template itself (7, 12, 95 
28), overall sequence similarity (6, 7, 10, 12) and local sequence context of recombining sequences 96 
(28-30). Using both in vitro assays and single cycle HIV-1 vectors, recombination hotspots have been 97 
identified in the untranslated regions (UTRs) (30-32), in gag (29, 33) and in env (28, 34). However, 98 
only limited information on recombination is available within other regions of the HIV-1 genome 99 
(33). We and others have attempted to use direct sequencing to locate recombination hotspots 100 
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within the HIV-1 genome (24, 33, 35), but the large amount of sequencing data required made it 101 
impossible to draw firm conclusions with strong statistical support.  102 
In this study, we made use of next generation sequencing to perform a comprehensive analysis of 103 
HIV-1 recombination using the marker method, with two marker configurations in gag and pol that 104 
allows recombination to be measured over 13 and 26 regions, respectively. This configuration is 105 
uniquely high resolution, with regions (separated by adjacent marker points) ranging from 21-159 106 
nucleotides in length. Additionally, the system has broad coverage within gag and pol. We develop a 107 
statistical approach for comparing recombination rates and find that the recombination is not 108 
constant along the genome, but varies with nucleotide position. This variation is statistically 109 
significant, with some regions showing a six-fold difference in recombination rate. We identify 7 110 
hotspots and 3 cold spots in gag; and 5 hotspots and 7 cold spots in pol. Hotspots appear in gag at 111 
the beginning of matrix, the matrix/capsid junction and the capsid/p2 junction and in pol at the 112 
protease-p51 junction. We found no hotspots around regions that have been implicated with 113 
protease inhibitor and reverse transcriptase inhibitor drug resistance mutations. We also analyse 114 
recombination rates using a virus with a completely different set of engineered marker points, and 115 
find that differences in recombination rate are not simply due to our silent marker manipulation of 116 
the viral sequence. Our results show that the viral gene region is a strong independent predictor of 117 
recombination rate. 118 
Materials and Methods 119 
Molecular Clones 120 
pDRNLMKlow (Genbank KC771033) and pDRNLMKhigh (Genbank KC771034) are minimally modified 121 
plasmids based on the prototypic HIV-1 strain pDRNL43. pDRNL43 is itself a derivative of pNL43, 122 
which originates from Ron Desrosiers (New England Primate Research Center) and is modified to 123 
remove 1.5Kb of cellular DNA flanking the HIV-1 genome in the pNL43 construct (36).  The modified 124 
plasmids are altered in gag to include 17 and 15 marker points, and in pol to include 16 and 34 125 
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marker points for pDRNLMKlow and pDRNLMKhigh, respectively. Marker points consist of, where 126 
possible, two single base pair changes in adjacent codons. This strategy allows us to distinguish 127 
easily between mutations introduced during the experimental procedure and real recombination. 128 
Furthermore, these marker points do not change any viral protein sequence or known RNA 129 
sequence elements, such a splice sites, and were rationally designed to minimize structural changes 130 
to the HIV-1 genome. Sequences were synthesised commercially (Genscript) and cloned into the 131 
ApaI and SpeI (gag) and XbaI and NotI (pol) sites of pDRNL43. pDRNLMKlow and pDRNLMKhigh were 132 
converted from the X4 tropic phenotype to the R5 phenotype, to generate pDRNLAD8MKlow and 133 
pDRNLAD8MKhigh by exchanging the Env gene from the pDRNLAD8 using the EcoRI and BamHI 134 
restriction sites.  These modifications were well tolerated as the protein processing profile and the 135 
abilities to establish infection via reverse transcription were not affected, enabling us to accurately 136 
quantify the recombination processes during primary cell infection. 137 
Recombination assay 138 
We produced pools of homozygous virus (virus containing identical genomes) by transfecting wild 139 
type and marker virus plasmids separately, and produced heterozygous virus (virus containing two 140 
different genomes) by co-transfection of the wild type and marker plasmids. Viral particles from 141 
clarified transfection supernatants were further purified by sequential filtration through 0.8 μm and 142 
0.45 μm sterile syringe filters (Sartorius). Purified virus was then concentrated by ultracentrifugation 143 
through a 20% sucrose cushion using an L-90 ultracentrifuge (Beckman Coulter) at 100,000 × g for 1 144 
h at 4°C. Pellets were resuspended in media and the virus quantified by enzyme-linked 145 
immunosorbant assay (ELISA) (Vironostika). Concentrated virus stocks were supplemented with 2 146 
mM MgCl2 and treated with 90 units/mL of Benzonase (Sigma) for 15 min at 37°C before infection to 147 
remove any contaminating plasmid DNA. Peripheral blood mononuclear cells (PBMCs) were isolated 148 
from buffy coats of HIV-1 seronegative blood donors (supplied by the Red Cross Blood Bank Service, 149 
Melbourne) by density gradient centrifugation over Ficoll-Plaque Plus (Amersham Biosciences). The 150 
identities of the blood donors from Red Cross are anonymous. Peripheral blood lymphocytes (PBLs) 151 
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were purified from PBMCs and stimulated in media (2 ×  106 cells/ml) supplemented with 10 μg/ml 152 
phytohemagglutinin (PHA) (Murex Diagnostics) and 10 units/ml human interleukin-2 (IL-2) (Roche 153 
Applied Science) for 2 days in Teflon-coated jars. After 2 days, PBLs were resuspended in fresh media 154 
containing 10 units/ml human interleukin-2 (IL-2) (Roche Applied Science) and incubated for a 155 
further 2 days before infection. Stimulated PBLs were infected with equal amounts of either 156 
homozygous or heterozygous virus, as determined by a HIV-1 antigen (p24 CA) micro ELISA assay. 157 
Heat inactivated (2 hr at 56°C) control infections were carried out to confirm efficient removal of 158 
plasmid DNA for each sample. 6 hr post-infection 10 µg/mL T-20 (NIH AIDS Reagent Program) was 159 
added to the cells to prevent second round replication. At 24 hr post PBL infection, cells were lysed 160 
and full-length reverse transcriptase products were quantified. Reverse transcription products were 161 
amplified using 10 sets of primers, generating 10 overlapping PCR amplicons (see primers). The 162 
following 2-step cycling conditions were chosen to minimize PCR induced recombination, as 163 
previously described (37): initial copy number 2,500, denaturation 98oC for 30 sec, followed by 72oC 164 
for 2 min for 29 cycles. PCR products for sequencing were created by pooling at least 4 independent 165 
PCR reactions per condition. Unique 6 nucleotide identifiers (barcodes) were attached using a 166 
modified parallel tagged sequencing protocol to allow multiplexing on the same sequencing run (38). 167 
Emulsion PCR and sequencing were performed at the Institute for Immunology and Infectious 168 
Diseases (IIID), Perth, according to standard GS FLX titanium procedures. In order to avoid re-169 
sampling, we generated our sequencing libraries in such a way as to ensure that it contained PCR 170 
products generated from over 10,000,000 original DNA molecules per plate of 454 sequencing run, 171 
whereas a single 454 sequencing run has sequencing capacity of ~1 million reads. We note that in 172 
any event, resampling per se would not lead to an increase in recombination rates. 173 
Primers 174 
Overlapping PCR amplicons for sequencing were generated using 10 sets of primers: G1(2945)Fw 175 
GAGATGGGTGCGAGAGCGTC and G1(3314)Rv TGTGTCAGCTGCTGCTTGCTG; G2(3236)Fw 176 
ACCAAGGAAGCCTTAGATAAGATAGAGGAAGAG and G2(3679)Rv 177 
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TGAAGGGTACTAGTAGTTCCTGCTATGTCACTTC; G3(3584)Fw GATAGATTGCATCCAGTGCATGCAG and 178 
G3(3955)Rv GCTTTTAAAATAGTCTTACAATCTGGGTTCGC; G4(3793)Fw 179 
TCTGGACATAAGACAAGGACCAAAGG and G4(4195)Rv ACATTTCCAACAGCCCTTTTTCCTAG; 180 
P1(4433)Fw GCGACCCCTCGTCACAATAAAGATAG and P1(4884)Rv 181 
GAGTATTGTATGGATTTTCAGGCCCAAT; P2(4695)Fw CACTTTAAATTTTCCCATTAGTCCTATTGAGACTG 182 
and P2(5110)Rv ACTAGGTATGGTAAATGCAGTATACTTCCTGAAG; P3(4951)Fw 183 
AAGAGAACTCAAGATTTCTGGGAAGTTCA and P3(5325)Rv CTCAGTTCCTCTATTTTTGTTCTATGCTGC; 184 
P4(5233)Fw CCAGACATAGTCATCTATCAATACATGGATGA and P4(5618)Rv 185 
CCAGTTCTAGCTCTGCTTCTTCTGTTAGTG; P5(5503)Fw TGGGCAAGTCAGATTTATGCAGG and 186 
P5(5934)Rv GTGGCTTGCCAATACTCTGTCCAC; P6(5774)Fw GAATGAAGGGTGCCCACACTAATG and 187 
P6(6166)Rv GCAAAGCTAGATGAATTGCTTGTAACTCAG. 188 
Data Processing 189 
In order to align, process and categorise the very large volume of sequencing data (>1 million 190 
sequences) that result from next generation sequencing, we used EMBOSS needle (39) and custom 191 
software written in BioRuby (39). After alignment to the genome, each sequence read was 192 
processed to identify regions that cover two markers points. Each region was then classified as 193 
recombination observed (if marker endpoints switched between marker type and wild type virus) or 194 
recombination not observed (if marker endpoints were identical). It is important to note that our 195 
marker points were designed so that all marker point contained at least two mutations in usually 196 
adjacent codons. Consequently, it is very unlikely that mutations introduced by the experimental 197 
setup, infection process or sequencing will artificially signal recombination. This is confirmed by the 198 
low rates of recombination in our controls. However, several marker points did exhibit poor 199 
sequence quality and alignment (regions PH1, PH2, PH3, PH4, PH5, PL1, PL2 and PL3, likely due to the 200 
presence of indels (either naturally or introduced by the marker point). As 454 sequencing has 201 
known issues with homopolymer sequences (40), and the sequence quality around these markers is 202 
vital for our analysis, the marker points showing poor sequence alignment (shown in black in Figure 203 
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4) are excluded from the analysis. These excluded markers and bordering regions represented a 204 
small fraction (~10%) of the pre-cleaned data.  205 
Recombination rates 206 
Recombination rates and confidence intervals were calculated in the statistical package R (41) using 207 
the linear model function “lm” on the optimal recombination rate, r, over all genome regions. For 208 
each interval, the recombination rate is calculated as 209 
 ݎ ൌ  ି୪୬ ሺଵିଶ௔ሻଶ௅   (1) 210 
where L is the nucleotide length of the genome region and a is the proportion of heterozygous 211 
sequences that observe a recombination for that region. This equation compensates for the 212 
probability of multiple (and therefore unobserved) recombination events between marker points 213 
(24). The number of heterozygous sequences is expected to be 50%, however this is directly 214 
estimated from the homozygous sequence frequency of each virus type using the method described 215 
in Schlub et. al. (24). The calculated recombination rate will represent an average recombination 216 
rate for each interval as the precise nucleotide position of the recombination event cannot be 217 
determined within the interval where parental sequences are identical. 218 
Comparing recombination rates 219 
We use two distinct marker configurations, where codon modifications occur on different 220 
nucleotides, to test if the choice of marker nucleotide position influences recombination rate 221 
fluctuations. To compare the results from the two configurations, we use marker system 1 to predict 222 
the recombination rate in marker configuration 2, and correlate this prediction with the 223 
experimental data for marker configuration 2. For each region in marker configuration 2, the 224 
prediction is calculated as the weighted average of recombination rates in overlapping regions from 225 
marker configuration 1, where the weighting is the proportion overlap (Figure 4B).  226 
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Correlations between datasets are performed in the statistical package R (41), using the ‘cor.test’ 227 
function. Correlations are Pearson correlations unless otherwise stated.  When correlating between 228 
marker configuration 1 and 2, adjacent regions in the marker configuration 1 prediction of marker 229 
configuration 2 will not be independent if a region from configuration 1 overlaps with two regions in 230 
configuration 2. To check whether this influences the correlation results presented, we define the 231 
dependence between two predictions that share an overlapping marker configuration 1 region to be 232 
the minimum weighting (percentage overlap) for those overlapping regions. Predictions with a 233 
dependence value over 10% are systematically removed to keep the maximal amount of data. The 234 
correlation coefficients and corresponding p-values resulting from this removal do not change 235 
substantially from those presented in the figures, and no significance levels or conclusions would be 236 
changed. Additionally using the non-parametric Spearman Rank correlation instead of the Pearson 237 
correlation does not change the significance of correlation co-efficient nor any of the conclusions.  238 
Controls for experimentally-associated recombination 239 
Our primary focus is on the viral recombination induced during reverse transcription of the HIV-1 240 
genome in vitro. However, recombination can also be experimentally induced at different stages of 241 
the procedure, such as during transfection of cell with plasmid, during PCR amplification, or during 242 
sequencing (37, 42-44). To ensure that the recombination rates presented are representative of the 243 
recombination rates experienced during a single cycle of HIV-1 replication, we comprehensively 244 
measured potential sources of artificial recombination. 245 
To measure any background recombination that might arise as a result of plasmid transfection and 246 
PCR amplification, we performed a number of controls. First, RNA was extracted from heterozygous 247 
virus using phenol chloroform based TRI reagent (Sigma Aldrich) according to the manufacturer’s 248 
recommendations and reverse transcribed into cDNA using SuperScriptTMIII (SSIII) (Invitrogen Life 249 
Technologies) and gene specific primer GAG4(4195)R: 5’ACATTTCCAACAGCCCTTTTTCCTAG 3’. This 250 
measured the transfection recombination rate to be approximately 5x10-6 REPN (recombination 251 
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events per nucleotide per round of infection), which corresponds to 0.25% of the total 252 
recombination rate reported in this study.  To control for potential recombination during in vitro cell 253 
-free reverse transcription, we also performed the same reverse transcription and processing on a 254 
mix of homozygous WT virus and homozygous MK virus (mixed in equal quantities (based on p24 255 
values) prior to RNA extraction, and were reverse transcribed in parallel with RNA extracted from 256 
heterozygous virus). We measure this rate to be 3x10-6 REPN (representing over half of the 257 
recombination occurring during our transfection control). Given that the recombination induced by 258 
SSIII is not present in our regular assay, this indicates that recombination occurring during 259 
transfection is even lower than our measured 5x10-6 REPN rate. Reverse transcription was 260 
performed in the presence and absence of SSIII, the latter condition providing a control for any 261 
plasmid contamination carried over from transfection.  Real time PCR was used to estimate viral 262 
cDNA copy number against a standard curve based on plasmid pDRNL(AD8) using primers 263 
GAG1(2945)F: 5’ GAGATGGGTGCGAGAGCGTC 3’ and GAG1 (3314)R: 5’ TGTGTCAGCTGCTGCTTGCTG 264 
3’.  Again, template viral cDNA were amplified using optimized PCR conditions outlined in the 265 
recombination assay section above.  266 
To assess background recombination introduced by PCR, we amplified a 1:1 mixture of WT and MK 267 
plasmid and sequenced the resulting DNA (PCR control plasmid). As a more stringent PCR control, 268 
we infected cells with an equal mixture of homozygous wild type and homozygous marker virus and 269 
subsequently PCR amplified and sequenced the resultant cDNA (PCR control cDNA). As each 270 
infection is the product of a homozygous virion, any intra-virion recombination will be effectively 271 
‘silent’ (since both strands are identical). Thus any recombination observed between WT and MK 272 
virus must have occurred due to chimera formation during PCR amplification (or less likely due to 273 
recombination occurring between virions in the infected cell). We calculate the average cumulative 274 
background rate of PCR induced recombination to be 2.9x10-4 REPN, well below that of the 275 
recombination rate in the experimental sample. Three regions (GH1, PH23 and PH25) did exhibit a 276 
higher risk of recombination in some (but not all) controls. As a precaution, these were removed 277 
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from all data analysis (Figure 4). After removal, the average induced recombination rate was 2.2x10-4 278 
REPN.  279 
Generalized linear models 280 
Generalized linear models (GLMs) were performed in the statistical package R (41), using the ‘glm’ 281 
function with a binomial error distribution. For each region the relationship between the estimated 282 
parameter (recombination rate) and experimental data (number of observed recombinations) 283 
depends on region nucleotide length and the proportion of heterozygous sequences (equation 1). To 284 
compensate for these factors, and ensure the binomial error distribution a custom link function 285 
identical to equation 1 was used. The factors viral phenotype, blood sample donor and interval 286 
region were tested with a process of forward addition. Statistical significance of the covariates was 287 
tested using a chi-squared test during an analysis of deviance. 288 
Results 289 
Experimental system 290 
We developed a system that can measure recombination between highly similar genomes by 291 
rationally designing codon modifications into the full length HIV-1 genome. This system contains no 292 
foreign gene inserts that could alter the folding of the RNA genome, and we avoided RNA sequences 293 
that were known to fold into functional RNA structures, such as splice or frameshifting sites. We 294 
further minimized structural changes to the RNA genome by only using silent adenine-to-guanine or 295 
cytosine-to-thymine (uracil) substitutions. That is, whilst all genetic changes have the potential to 296 
alter RNA structure, adenine and guanine both form Watson-Crick base pairs with the RNA base 297 
uracil. Similarly, cytosine and thymine (uracil) both form Watson-Crick base pairs with the guanine. 298 
We reasoned that these substitutions are likely to have the least impact on global RNA structure, as 299 
they do not disrupt pre-existing base pairing. Finally, wherever possible, substitutions were only 300 
made if they occurred naturally in the HIV sequence compendium (45). These codon modifications 301 
do not change the ability to establish infection and the synthesis of viral cDNA via reverse 302 
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transcription. These modifications create 39 genome regions ranging from 21nt to 159nt in length 303 
over which recombination can be studied. We produced pools of homozygous virus (virus containing 304 
identical genomes) by transfecting wild type and marker virus plasmids separately, and produced a 305 
mixture of homozygous and heterozygous virus (virus containing two different genomes) by co-306 
transfection of the wild type and marker plasmids. We performed a single round infection in 307 
peripheral blood mononuclear cells (PBMCs) with pools of heterozygous and homozygous virions, 308 
after which recombination can be detected with high throughput sequencing of cDNA. The 309 
recombination rate between marker points was calculated with equations that (1) estimate the ratio 310 
of heterozygous to homozygous infections (2) compensate for the nucleotide length over which 311 
recombination is measured and (3) compensate for the probability of multiple (unobserved) 312 
recombination events between marker points (24) (see materials and methods).  313 
Recombination rate fluctuates within gag and pol. 314 
We first measured the recombination rate across our two regions of interest in gag and pol. We 315 
sequenced approximately 86,000 genome regions pooled from 5 donors and measured an average 316 
recombination rate of 2.0x10-3 recombination events per nucleotide per round of infection (REPN), 317 
corresponding to approximately 19-20 recombination events per genome (95% C.I. 1.8x10-3 to 318 
2.2x10-3 REPN). When we segregated our data into the two regions, gag and pol, we found weak 319 
evidence for a different recombination rate, with an average recombination rate of 2.3x10-3 and 320 
1.8x10-3 REPN, respectively (p=0.07, t-test on interval recombination rates). An advantage of our 321 
high-resolution marker system is the ability to investigate if recombination levels change with 322 
nucleotide position. Interestingly, we found a large level of fluctuation in recombination rate in 323 
different segments of the genome, where individual genome region’s rates vary from 0.51x10-3 REPN 324 
to 3.4x10-3 REPN – a greater than 6-fold difference (Figure 1). This indicates that the recombination 325 
rate is not constant along the HIV-1 genome and that recombination hot and cold spots may exist. 326 
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To investigate this further, we sought to determine if the locations of putative recombination 327 
hotspots were consistent across two viral phenotypes that enter different subpopulations of T-328 
lymphocytes via distinct co-receptors (CCR5 and CXCX4), and between unrelated blood donors. We 329 
found a significant and high correlation for the recombination rates in identical intervals when we 330 
compared between the R5 and X4 viral phenotype (r = 0.69, p < 0.0001, Figure 2A-B), and between 331 
blood donors (Figure 2C, Table 1). This provides strong evidence that the locations of putative 332 
recombination hotspots are similar between these groups, and also constant across multiple 333 
independent infection experiments, indicating a systematic change in recombination rate along the 334 
genome. 335 
The recombination rates presented above theoretically include the cumulative effect of 336 
experimentally induced recombination during DNA transfection and subsequent PCR (46). To 337 
demonstrate that these experimentally induced rates are not the source of recombination hotspots, 338 
we independently measured the experimentally induced recombination rates (see Materials and 339 
Methods). We addressed whether transfection induced recombination could influence our 340 
recombination rates by directly measuring recombination rates on RNA extracted from heterozygous 341 
virions produced from cells co-transfected with WT and MK plasmids. We used SuperScript III 342 
(RNaseH-, recombination defective) to reverse transcribe RNA before subjecting it to PCR and 343 
sequencing using the same conditions as the experimental samples. This experiment measured the 344 
accumulation of recombination due to transfection, in vitro SuperScript III reverse transcription and 345 
PCR. This rate was calculated to be 5x10-6 REPN. For completeness, we also included two controls to 346 
dissect the contribution of PCR induced recombination and a further control to measure the 347 
contribution of SuperScript III recombination (see Materials and Methods). Although we did see 348 
some variation in the level of experimental recombination between experimental replicates, under 349 
all cases, we found that overall recombination rates were too low to introduce significant bias, in 350 
agreement with our previous results (24). We also measured the rate of recombination for each 351 
interval and found that the infrequent experimental recombination was not localised to hotspots but 352 
15 
 
evenly spread over gag and pol (data not shown) Three regions (GH1, PH23 and PH25) did exhibit a 353 
higher risk of recombination in some (but not all) controls. As a precaution, these were removed 354 
from the analysis for this paper (see materials and methods). To further check that these low levels 355 
of recombination are not driving the recombination hotspots we correlate the recombination rate 356 
between intervals in our experimental and biological sample. We found that the recombination rates 357 
following infection do not significantly correlate with the experimentally induced recombination rate 358 
(PCR cDNA recombination rate r = 0.02, p = 0.93; transfection recombination rate: r = 0.03, p = 0.93) 359 
(data not shown). Therefore the rates presented in this study are not biased by the experimental 360 
method, and provide an accurate view of HIV-1 recombination hotspots within the genome regions 361 
defined by our marker points. 362 
Recombination rate hotspots are not a product of experimental marker design 363 
The HIV-1 genome used in this study includes a number of introduced silent codon modifications to 364 
act as markers for recombination. These modifications were designed so that they did not alter any 365 
viral proteins or known RNA elements. However, as nucleotide sequence can influence 366 
recombination frequencies (47), we sought to investigate whether the choice of codon modifications 367 
was driving the variation in recombination rate observed in Figure 1. To test this, we created an 368 
additional viral phenotype MKlow with more broadly spaced marker points at different nucleotide 369 
positions within gag and pol (original phenotype: MKhigh)(Figure 4A, schematic of two marker 370 
systems). As with MKhigh, these modifications do not change the viral protein sequence or the in vitro 371 
infectivity of the virus (data not shown). If the putative recombination hotpots measured in MKhigh 372 
(Figure 1) are purely driven by sequence disruption due to codon modification, then the location of 373 
the hotspots in marker system MKlow will be different (as markers are at different nucleotide 374 
positions). Conversely, if the hotspot locations for MKhigh and MKlow are similar, then this provides 375 
evidence that the variations in recombination rates are intrinsic to the viral genome and not a 376 
product of our codon modification. 377 
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The regions that measure the recombination rate in the two marker systems do not perfectly align 378 
(due to different marker codon nucleotide position, Figure 4) which makes it difficult to directly 379 
compare recombination rates at different sites between the two marker systems. To overcome this, 380 
the recombination rates from marker system MKhigh were interpolated to predict the recombination 381 
rate using the new (more broadly spaced) marker system MKlow (Figure 4B, schematic of 382 
interpolation between marker systems, materials and methods). In this way, the recombination 383 
rates expected from the experimental rates in MKhigh and the overlap between MKhigh and MKlow can 384 
be compared with the experimentally observed rates for MKlow using a correlation analysis. Although 385 
this interpolation from high resolution to low does reduce the information available in the high 386 
resolution, and increase variability making a correlation harder to detect, it is necessary to directly 387 
compare the resolutions.  We found that the recombination rate between marker sets is significantly 388 
correlated (r = 0.42, p = 0.03 for R5, r = 0.72, p < 0.001 for X4, Figure 3A-D) indicating that in general 389 
genomic regions with a high/low recombination rate in MKhigh also have a high/low recombination 390 
rate in MKlow. Therefore recombination hotspot locations are consistent between the marker 391 
systems and these hotspots are not driven by the experimental codon modification.  392 
Finally, recombination rate variation may be influenced by other experimental factors and sampling 393 
error (together called ‘random variation’ for simplicity). To estimate how much random variation 394 
exists for this study, we correlate two identical experiments with identical marker systems (both 395 
MKhigh). If there were zero random variation, these two results should be identical and correlate 396 
perfectly. Therefore any deviation here provides a measure for the random variation in this study 397 
(Figure 3E-F). We found a high rate of correlation between experimental replicates (Figure 3F, r= 398 
0.78, p < 0.001), further highlighting that putative recombination hotspots are intrinsic to the HIV-1 399 
genome and not a product of other experimental factors.  400 
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Identifying the recombination hot and cold spots. 401 
We have shown that our procedure reliably estimates local recombination rate changes in gag and 402 
pol and that these changes are consistent across viral phenotypes, blood donors, and codon marker 403 
systems. Thus, the identified changes of recombination rate across the viral sequences are intrinsic 404 
to the HIV-1 genome. However to accurately determine hot or cold spots with recombination rates 405 
significantly different to the average, a number of additional factors need to be considered. These 406 
include: the estimated number of sequences sampled for each interval; the variance introduced by 407 
unrelated blood donors; and the variance introduced by the target cell (controlled by the two viral 408 
phenotypes, CCR5 and CXCR4). Generalized linear models (GLMs) provide an analytic framework for 409 
investigating the relationship between recombination rate and genomic position whilst accounting 410 
for the factors listed above. Generalized linear models generalize a multiple regression analysis, 411 
allowing for the binomial distribution of our sequence recombination data, and the adjustment for 412 
interval nucleotide length when calculating recombination rates.  413 
We used a process of forward addition to test and build the final GLM and to identify which 414 
covariates are significantly associated with recombination rate (Table 2). We find that recombination 415 
rate is significantly associated with viral phenotype (X4/R5, p < 0.001) and blood sample donor (p < 416 
0.001) (chi-square test on analysis of deviance). We also find that the interval along the genome over 417 
which recombination is measured is also significantly associated with recombination rate (p < 0.001). 418 
The final model which include viral phenotype, blood sample donor, and interval, provides very 419 
strong evidence that the recombination rate is not constant over gag and pol, and that this result is 420 
consistent over viral phenotype and blood sample donor. This final GLM estimates the 421 
recombination rate parameter for each interval. By calculating the standard error for these 422 
parameter estimates, the intervals with a recombination rate significantly different to the average 423 
rate, that is recombination hot/cold spots, can be identified. 424 
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Over the 39 regions, we found 12 statistically significant recombination hotspots and 10 statistically 425 
significant recombination coldspots (Figure 5, Table 3). Interestingly, these hot and cold spots are 426 
unequally distributed in gag and pol, with gag containing seven of the twelve hotspots, yet only 427 
three of the ten coldspots. In gag, hotspots appear to cluster around gene junctions, at the 428 
beginning of matrix, the matrix/capsid junction and the capsid/p2 junction (Figure 5B). In pol, we 429 
find one hotspot at the protease-p51 junction (Figure 5B), but find no hotspots in genome regions 430 
containing mutations that have been implicated in drug resistance. Therefore, recombination is less 431 
likely to influence the generation of multiple drug resistant HIV-1 within these regions as compared 432 
to regions of the HIV-1 genome containing recombination hotspots for the generation of 433 
recombinant HIV-1. 434 
Discussion 435 
The high replication rate of HIV-1 combined with high rates of mutation and recombination lead to 436 
remarkable adaptability of the virus in the face of intense evolutionary pressure. Recombination is 437 
thought to make natural selection more efficient by breaking linkages between mutations (48-50). 438 
That is, recombination helps to maintain genetic diversity by breaking linkages between 439 
advantageous and deleterious mutations, whilst also facilitating the removal of deleterious 440 
mutations by bring them together in the same genome. Importantly, recombination can also pair 441 
advantageous mutations, which can facilitate the acquisition of multiple drug resistance leading to 442 
treatment failure (48-54). Recombination may also be an important mechanism by which the virus 443 
eventually escapes immune control (55-58). However, recombination also has the potential to 444 
inhibit adaptation and evolution depending on epistasis and genetic drift (51). Consequently, an 445 
improved understanding of recombination is important for understanding the evolutionary history 446 
of HIV-1 and may help to guide the design of robust antiretroviral therapies.  447 
There have been many studies showing that even in the absence of selection recombination does 448 
not occur randomly on the HIV-1 genome, highlighting the presence of additional factors governing 449 
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the recombination process (11, 19, 28-35, 59). However, many of these studies do not measure 450 
recombination rate in their natural genome context, or they measure recombination between highly 451 
divergent genomes that may not be most representative of the situation in vivo, where we expect 452 
recombination between closely related members of the viral quasi-species. Here, we present a 453 
system that allows the study of recombination between highly similar genomes that mimic the HIV-1 454 
quasispecies within an HIV-1 infected patient. We delineate the process of retroviral recombination 455 
through infection of primary T lymphocytes with a minimally codon modified full-length virus. An 456 
advantage of this method is that we can target specific areas of the genome whilst controlling the 457 
length of interval and hence the accuracy of our study. We have previously used a similar system to 458 
analyse recombination rates in a small region of gag (37). In this case, we were unable to draw 459 
conclusions about the location of recombination hotspots primarily because this requires analysis of 460 
large numbers of sequences (19, 35, 37).  In this study, we applied next generation sequencing to 461 
systematically measure at high-resolution recombination rates in gag and pol. These two genome 462 
regions were chosen because of their importance in the generation of drug resistant virus and 463 
immune escape mutations (60).  464 
We have optimised this system and shown that it is not biased by confounding factors related to 465 
experimentally induced recombination and for the occurrence of multiple template switches over 466 
intervals of varying lengths (24, 37). Using two independent sets of marker modification, we show 467 
that putative recombination hotspots are not due to modifications introduced by our marker 468 
system. Indeed, there is a high correlation of recombination hotspots between our two systems. 469 
Notably, regardless of viral phenotype and blood donor, we demonstrate greater than 6-fold 470 
recombination rate changes across gag and pol. These changes are consistent regardless of viral 471 
phenotype (r = 0.68, p < 0.001) and blood donor (r = 0.44-0.71, p = <0.001 – 0.04). We identify 12 472 
genome regions with significantly higher rates of recombination and 10 genome regions with 473 
significantly lower rates of recombination.  474 
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It is instructive to compare our recombination hotspots between closely related genomes with those 475 
identified in natural HIV-1 sequences. Surprisingly, the gag hot/cold spots identified in our study 476 
match closely with those identified by analysing patient sequences (6, 9, 61). This is surprising 477 
because regions of sequence similarity are presumed to drive inter-subtype recombination, and one 478 
would not expect to see the impact of local recombination hotspots after so many confounding 479 
factors such as selection for functional proteins, drug resistance or from the immune system (9, 62). 480 
One of the most comprehensive studies, by Simon-Loriere and colleagues analysed sequences 481 
retrieved from the Los Alamos National Laboratory HIV sequence database (http://hiv-482 
web.langl.gov) provides evidence of recombination (9). Their study identified two hot spots and one 483 
cold spot in capsid of gag, corresponding to our regions GH5-GH8, GH12-GH13 and GH9-GH10, 484 
respectively. These regions also corresponded to hot and coldspot clusters in our analysis. The hot 485 
region spanning GH5-GH8 does include a sub-region with a strong and significant cold spot (GH6; -486 
0.73x10-3, p<0.0001) that is not present in the Simon-Loriere study. However, this sub-region may 487 
have been missed in their data set as the segment GH6 is only 21 bp in length, and they averaged 488 
their recombination breakpoints using a sliding window of 200 nt. It is interesting to note that these 489 
two hot regions span the Matrix-Capsid and Capsid-P2 junctions of Gag. Indeed, it has been 490 
proposed that the distribution of RNA structures along the HIV-1 genome has evolved to facilitate 491 
gene swapping in a way that maximises genetic diversity whilst minimizing the chance that the 492 
resulting progeny is impaired (9, 61). Our study does not directly address this issue as our marker 493 
points were designed to minimize structural changes to the genome. However, our data showing the 494 
position of hot and cold spots in the genome will help to inform future mechanistic studies into the 495 
factors that influence recombination. 496 
Within pol, some of our hot spots do not match those found by analysing patient sequence 497 
databases. In our data set, we observe a hotspot near the beginning of p51 (PH6; 0.74x10
-5; p<0.05) 498 
that is followed by a region of intermediate recombination ending with a strong recombination cold 499 
spot at PH12 (-0.66x10
-5; P<0.0001). In the Simon-Loriere study, they identify a broad hot spot 500 
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beginning at region PH6 and peaking at PH11. Thus, where their study finds one of their strongest hot 501 
spots, we find a region of intermediate recombination ending with one of our coldest spots at Ph12. 502 
As this region contains important resistance mutations, such as the thymidine analogue mutations 503 
(TAMS) (60), the detection of hotspots for recombination in the in vivo data could be evidence for 504 
selection. Similarly, we identify a cold spot (PH31; -0.75X10
-5; P<0.001) that falls close to the p51-505 
RNase H junction, which was labelled as a hotspot for recombination in the Simon-Loriere study. On 506 
the other hand, we identify hot spot PH19 (0.54x10
-5; <0.05), which falls within an unstructured 507 
peptide loop of RT (63). Interestingly, this hot region PH19-H21 corresponds exactly to some of the 508 
most highly structured RNA in the HIV-1 genome, as measured by SHAPE chemistry (63). Indeed, 509 
RNA structures are proposed to favour recombination by causing reverse transcriptase to pause on 510 
the template (12, 27, 64-66), and mechanistic studies demonstrate that the presence of RNA 511 
structure is often a feature of recombination hotspots (34, 67). It has been previously reported that 512 
HIV-1 gene junctions are both enriched in RNA structure and thus more recombinogenic than other 513 
regions of the HIV-1 genome (61, 63) We anecdotally note that our recombination hot spots do 514 
seem to be enriched at gene junctions, with the exception of the RNase H junction. This suggests 515 
that local fluctuations in recombination rates could drive the evolution of the RNA genome on a 516 
global scale. Further investigation of these genomic locations is warranted as the molecular 517 
mechanisms that cause recombination hot and cold spots may shed further light on the higher-level 518 
organisation of the HIV-1 genome. 519 
As recombination is thought to facilitate viral evolution by intermixing immune escape and drug 520 
resistance mutations within HIV-1 gag and pol, knowledge of how recombination rates vary within 521 
these particular (68) regions of the viral genome is of importance for designing antiviral strategies. 522 
From a therapeutic viewpoint, the shuffling of resistance mutations within gag and pol could impact 523 
the generation of multiple drug resistant virus (48-50). In general, the further apart genomic regions 524 
are, the less likely they will be linked together, and the easier it will be to shuffle mutations between 525 
these regions. For genomic regions that are close together, it should be easier to generate a RT 526 
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double mutation where the resistance mutations are separated by a recombination hotspot. Our 527 
data suggests the major reverse transcriptase drug resistance mutations lie in a relatively stable 528 
region of the genome, theoretically ‘reducing’ the risk that they will be brought together by 529 
recombination. It is important to note, however, that an important prerequisite for recombination is 530 
the co-packaging of genetically distinct genomes into viral particles via efficient co-infection of cells. 531 
Early studies suggested that these conditions were likely to be fulfilled in vivo, with between 75-80% 532 
of infected spleen cells harbouring at least two or more proviruses, with most of these cells 533 
harbouring genetically distinct proviruses. (69). More recent studies on both CD4+ T cells and 534 
infected spleen cells contradict this view, and show that the majority of cells are only singly infected 535 
(68, 70). Nevertheless, there is ample evidence that at least some recombination does occur in vivo, 536 
and that it is functionally relevant to immune escape and the generation of multiple drug resistant 537 
HIV-1 (48-52, 54-58, 68). Furthermore, it is possible that the location of recombination hotspots may 538 
be more important under scenarios of low co-infection compared to scenarios where the conditions 539 
for recombination are rampant. It will be important to test this assertion by including the possibility 540 
of recombination hotspots in models of HIV-1 dynamics. 541 
Altogether, our data provide unique insights into HIV-1 recombination occurring between highly 542 
similar genomes likely to be found in the majority of infected individuals. Our results demonstrate 543 
that recombination does not occur randomly, and we identify recombination hot-spots and cold-544 
spots in gag and pol. Importantly, our recombination hot / cold spots match closely with those found 545 
by analysis of patient sequence databases, indicating that, for gag and pol, the recombinogenic 546 
properties of RNA genome itself, rather than sequence similarity is likely to be the main driver of 547 
recombinant genomes circulating in the human population. Further studies into this area may 548 
ultimately prove crucial in developing robust antiviral strategies against HIV-1. 549 
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Figures 779 
Figure 1: Recombination rate variation in gag and pol. Recombination rates were measured in 39 780 
genome regions ranging from 21nt to 159nt in length (denoted by horizontal bars) in gag and pol. 781 
The average number of recombination events per nucleotide per round of infection (REPN) are 782 
shown on the y-axis with nucleotide position relative to the beginning of the NL43 5’ LTR shown on 783 
the x-axis. 784 
Figure 2: Recombination rate hotspots are consistent between viral phenotypes and PBMC blood 785 
donors. (A,C) Recombination rates are compared between two viral phenotypes R5 and X4 and 786 
between 5 blood donors with the average number of recombination events per nucleotide per 787 
round of infection (REPN) shown on the y-axis and nucleotide position relative to the beginning of 788 
the NL43 5’ LTR shown on the x-axis (B) Correlation between the recombination rates of two viruses 789 
differing in viral phenotype, with REPN shown on both axes. 790 
Figure 3: Recombination hotspots are not a product of marker design. To check if recombination 791 
rate hotspots are driven by the choice of silent codon modifications we measured the recombination 792 
rate in two different marker configurations, MKhigh and MKlow for (A) CCR5(R5)-tropic viruses (C) 793 
CXCR4(X4)-tropic virus, and performed viral replicates of identical virues (E). (A, C, D) Recombination 794 
rates with the average number of recombination events per nucleotide per round of infection 795 
(REPN) shown on the y-axis and nucleotide position relative to the beginning of the NL43 5’ LTR 796 
shown on the x-axis. (B, D) Correlations between the recombination rates of MKhigh and MKlow viruses 797 
with REPN shown on both axes. (F) Correlation between the recombination rates of MKhigh replicate 798 
infections with REPN shown on both axes. Correlations are Pearson product moment correlations. 799 
Figure 4: Schematic of marker configurations, and how to compare between them. (A) In this 800 
study, recombination is measured between wildtype virus and a marker system with silent codon 801 
modifications ‘markers’ that do not affect any viral proteins or packaging (marker configuration 802 
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MKhigh). To test that these codon modifications do not influence our recombination rate 803 
measurements, a second marker system virus is created where the codon modifications occur at 804 
different nucleotide positions (marker configuration MKlow). (B) To compare between marker 805 
configurations, MKhigh is used to predict what would be measured as the recombination rate, if MKlow 806 
was used. This prediction can them be directly compared to the experimental results for MKlow. For 807 
each interval in MKlow the MKhigh prediction is calculated by averaging the overlapping MKhigh 808 
interval’s recombination rate, and weighting this average by the proportion of overlap. 809 
Figure 5: 95% confidence intervals for the recombination rate in each region for the R5 phenotype. 810 
We fit a generalized linear model to the dataset to calculate the statistical significance of 811 
recombination hot and cold spots, after accounting for confounding factors such as viral phenotype 812 
and donor. The model estimates the standard error in recombination rate for each genome region, 813 
from which a 95% confidence interval is obtained. Those intervals that do not overlap the average 814 
rate are bolded. (A) Recombination rate per nucleotide for each genome segment in R5 averaged 815 
over all donors. Horizontal bars represent the length of the genome region. 95% confidence intervals 816 
are Bonferroni corrected for the multiple comparisons.  (B) Statistically significant hot and cold spots 817 
corresponding to genome location. 818 
 819 
R5 virus Donor 2 Donor 3 Donor 4 Donor 5 
Donor 1 r = 0.58, p = 0.003 r = 0.71, p < 0.001 r = 0.58, p < 0.001 r = 0.66, p < 0.001 
Donor 2  r = 0.44, p = 0.04 r = 0.58, p = 0.003 r = 0.64, p < 0.001 
Donor 3   r = 0.54, p = 0.001 r = 0.61, p < 0.001 
Donor 4    r = 0.63, p < 0.001 
Table 1: Between patient correlations for R5. To investigate whether recombination hot and cold 820 
spot locations are similar across different donors, the recombination rate for each interval and 821 
donor was calculated (Figure 2C). The pair-wise correlations on the interval specific recombination 822 
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rate across donors were all positive and significant, indicating that recombination hot and cold spot 823 
locations are consistent across donors. 824 
Model 
number 
Description Residual 
deviance 
DF (# of 
parameters) 
p-value (when 
compared to model) 
1 One average recombination rate 1883 274 (1)  
2 Rate depends on virus 1813 273 (2) <0.001 (1) 
3 Rate depends on donor 1470 270 (5) <0.001 (1) 
4 Rate depends on virus and donor 1424 269 (6) <0.001 (1, 2 or 3) 
5 Rate depends on virus, donor and 
interval 
696 231 (44) <0.001 (4) 
Table 2: Generalized linear models (GLMS) fitted. GLMs are a good analytic framework for 825 
investigating the effects of nucleotide position on recombination rate after accounting for the 826 
confounding effects of virus phenotype and blood donor. To build up the appropriate complexity for 827 
this analysis, a base model (model 1) with one average recombination rate fitted to all of the data 828 
pooled together was created. We next fitted more complex models with a recombination rate for 829 
each virus (model 2), a recombination rate for each donor (model 3) and a recombination rate that 830 
depends on both donor and phenotype (model 4). These models increase the number the 831 
complexity of the analysis which is reflected in the increase in number of parameters and decrease 832 
in the degrees of freedom (DF column). However, this increased complexity is statistically justified, 833 
as the reduction in deviance (a measure of error in the model) is sufficiently large. This indicates that 834 
viral phenotype and donor are confounding effects and should be included in the final model. In the 835 
final model recombination rates depend on phenotype, donor and genome interval (model 5). This 836 
model’s increase in complexity is also justified by the reduction in deviance. The final model shows 837 
that genome position is an independent predictor for recombination rate, that the hot and cold 838 
spots we observe in our data are statistically significant, and that the location of recombination hot 839 
and cold spots are consistent across viral phenotypes and donors.  840 
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 841 
Interval 
RR 
difference 
to mean 
(x10-3) 
P-
value 
Nucleotide 
Position start 
(from 5' LTR) 
Nucleotide 
Position end 
(from 5' LTR) 
Interval 
length 
Amino 
Acid 5' 
interval 
Amino 
Acid 3' 
interval 
GH2 0.38 <0.001 912 984 72 E42 Q65
GH3 -0.09   984 1032 48 P66 T81 
GH4 -0.10   1032 1113 81 I82 Q108 
GH5 0.51 <0.001 1113 1266 153 N109 V159 
GH6 -0.74 <0.001 1266 1287 21 E160 P166 
GH7 0.49 <0.001 1287 1374 87 E167 Q195 
GH8 0.55 <0.001 1374 1476 102 A196 R229 
GH9 -0.31   1476 1524 48 E230 E245 
GH10 -0.56 <0.001 1524 1560 36 Q246 P257 
GH11 0.32 <0.05 1560 1719 159 V258 S310 
GH12 0.95 <0.001 1719 1821 102 Q311 E344 
GH13 1.11 <0.001 1821 1896 75 E345 Q369 
GH14 -0.31 <0.05 1896 1947 51 V370 Q386 
PH6 0.78 <0.05 2573 2615 42 V8 K22 
PH7 -0.22   2615 2651 36 Q22 L34 
PH8 -0.55   2651 2681 30 V34 E44
PH9 0.55   2681 2726 45 G44 P59 
PH10 -0.17   2726 2771 45 V59 L74
PH11 0.11   2771 2825 54 V74 L92 
PH12 -0.63 <0.001 2825 2870 45 G92 T107
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PH13 0.45   2870 2909 39 V107 L120 
PH14 -0.02   2909 2966 57 D120 T139
PH15 -0.54 <0.05 2966 3011 45 P139 K154 
PH16 -0.46   3011 3065 54 G154 R172
PH17 0.32   3065 3116 51 K172 V189 
PH18 -0.10   3116 3167 51 G189 R206
PH19 0.57 <0.01 3167 3218 51 Q206 K223 
PH20 0.43 <0.05 3218 3290 72 E223 P247
PH21 -0.93 <0.001 3290 3326 36 E247 K259 
PH22 -0.46 <0.001 3326 3383 57 L259 Q278
PH24 -0.49 <0.01 3425 3479 54 V292 L310 
PH26 -0.13   3530 3599 69 A327 K350
PH27 0.11   3599 3650 51 T350 Q367 
PH28 0.68 <0.01 3650 3680 30 L367 T377
PH29 0.41 <0.05 3680 3746 66 E377 E399 
PH30 0.46   3746 3815 69 A399 L422
PH31 -0.72 <0.01 3815 3860 45 V422 A437 
PH32 -0.35   3860 3905 45 E437 L452 
PH33 -1.29 <0.001 3905 3930 25 G453 D460 
Table 3: Locations of hotspots and coldspots. Using the final GLM (Table 2, model 5) we predicted 842 
the recombination rate for each interval after adjusting for the effects of viral phenotype and donor 843 
variability (Figure 5). From the estimate of standard error for each interval, we determined which 844 
regions are significantly different to the average recombination rate across gag and pol. Intervals 845 
without p-values were not significant at the 0.05 level. 846 
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